{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-007279","form_type":"8-K","ticker":"ODYY","cik":"0001626644","company_name":"Odyssey Health, Inc.","filed_at":"2022-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.484855+00:00","generated_at":"2026-06-22T07:01:16.339214+00:00","sec_items":["1.01","5.02","7.01","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Odyssey Health hires CCO and COO for NeuroPharma; salaries contingent on $5M fundraising","bullets":["Erik Emerson named CCO and Greg Gironda named COO of Odyssey NeuroPharma, effective Nov 1, 2022.","Each receives one-year term at 33% part-time commitment; base salary of $125K payable only after company raises $5M.","Each granted 600K stock options: 125K vest on signing, 300K upon $5M+ financing, 175K upon Nasdaq/NYSE listing.","Executives bring over 50 years combined pharmaceutical commercialization experience.","Odyssey aims to advance concussion and Niemann-Pick treatments through Phase II trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-007279","json":"https://secwatch.observer/filing/0001683168-22-007279.json","markdown":"https://secwatch.observer/filing/0001683168-22-007279.md","text":"https://secwatch.observer/filing/0001683168-22-007279.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626644/000168316822007279/0001683168-22-007279-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626644/000168316822007279/odyssey_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T07:01:16.339214+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"85af3111a0","claim":"Greg Gironda was appointed as Chief Operations Officer at Odyssey Health, Inc..","evidence_excerpt":"On November 1, 2022, the Company and Mr. Gironda entered into an employment agreement (the “Agreement”) for a one (1) year term as Chief Operations Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1626644/000168316822007279/0001683168-22-007279-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operations Officer"}],"fact_type":"executive_change"},{"claim_id":"b7c6c38c68","claim":"Erik Emerson was appointed as Chief Commercial Officer at Odyssey Health, Inc..","evidence_excerpt":"On November 1, 2022, the Company and Mr. Emerson entered into an employment agreement (the “Agreement”) for a one (1) year term as Chief Commercial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1626644/000168316822007279/0001683168-22-007279-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}